GlassScriptPhysician profile
Matthew Thomas Hoffmann
NPI 1609132976
$12,588.30
in general payments reported to CMS, 2019-2025
31 companies · $3,137 in 2025
The $3,137 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $776 · 2020: $527 · 2021: $1,655 · 2022: $1,898 · 2023: $2,344 · 2024: $2,252 · 2025: $3,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,715 · Education: $18.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,714.55 |
| Education | $18.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,702.29 | 2019-2025 | |
| Kerecis Limited | $1,409.60 | 2024-2025 | Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Marigen |
| Janssen Biotech, INC. | $1,286.61 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $1,170.25 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $1,049.41 | 2019-2025 | Taltz, Ebglyss |
| Genzyme Corporation | $972.96 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $665.51 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $476.75 | 2022-2025 | Sotyktu |
| Pfizer INC. | $357.82 | 2019-2025 | |
| Incyte Corporation | $340.48 | 2021-2025 | Opzelura |
| Amgen INC. | $252.56 | 2020-2024 | Otezla |
| Leo Pharma INC. | $242.19 | 2019-2022 | |
| Ucb, INC. | $211.90 | 2020-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $201.35 | 2019-2024 | Ilumya |
| Arcutis Biotherapeutics, INC. | $188.51 | 2023-2025 | Zoryve |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $186.28 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $143.43 | 2021-2025 | Cabtreo, Arazlo, Jublia |
| Galderma Laboratories, L.P. | $140.30 | 2020-2025 | Nemluvio |
| Genentech USA, INC. | $134.67 | 2019-2022 | |
| Almirall LLC | $106.64 | 2021-2025 | Seysara |
| Helsinn Therapeutics (U.S.), INC. | $96.42 | 2021-2022 | |
| Organon LLC | $93.63 | 2025 | Vtama |
| Janssen Scientific Affairs, LLC | $37.67 | 2020 | |
| Journey Medical Corporation | $34.64 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.06 | 2023 | |
| Vyne Pharmaceuticals INC. | $21.90 | 2020 | |
| Botanix Sb INC | $14.29 | 2025 | Sofdra |
| Sanofi-Aventis U.S. LLC | $12.74 | 2021 | |
| Mayne Pharma Commercial LLC | $12.44 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Hoffmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.